Cargando…

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring

Inflammatory bowel disease (IBD) is a chronic condition that significantly affects the quality of life of its patients. Biologic drugs have been the mainstay treatment in the management of IBD patients but despite their significant contribution, there remains a proportion of patients that do not res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albader, Farah, Golovics, Petra Anna, Gonczi, Lorant, Bessissow, Talat, Afif, Waqqas, Lakatos, Peter Laszlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515794/ https://www.ncbi.nlm.nih.gov/pubmed/34712029 http://dx.doi.org/10.3748/wjg.v27.i37.6231

Ejemplares similares

Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
por: Gonczi, Lorant, et al.
Publicado: (2019)

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
por: Strohl, Matthew, et al.
Publicado: (2018)

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
por: Al Khoury, Alex, et al.
Publicado: (2021)

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015
por: Golovics, Petra Anna, et al.
Publicado: (2022)

Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2019)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
por: Nene, Sofia, et al.
Publicado: (2020)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
por: Gonczi, Lorant, et al.
Publicado: (2017)

Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease
por: Alrajhi, Saad, et al.
Publicado: (2020)

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Updates in therapeutic drug monitoring in inflammatory bowel disease
por: Lodhia, Nilesh, et al.
Publicado: (2022)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease
por: Chao, Che-Yung, et al.
Publicado: (2019)

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary
por: Lontai, Livia, et al.
Publicado: (2023)

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article
por: Chao, Che-Yung, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
por: Kablawi, Dana, et al.
Publicado: (2023)

Endoscopic management of Crohn’s strictures
por: Bessissow, Talat, et al.
Publicado: (2018)

Hereditary Nonpolyposis Colorectal Cancer in Association with Crohn's Disease and Lynch Syndrome: The Importance of a Strict Endoscopic Surveillance
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges
por: Choden, Tenzin, et al.
Publicado: (2018)

Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians
por: Hart, Lara, et al.
Publicado: (2020)

Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease
por: Yasmin, Farah, et al.
Publicado: (2022)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
por: Pouillon, Lieven, et al.
Publicado: (2019)

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database
por: Kurti, Zsuzsanna, et al.
Publicado: (2018)

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Intestinal ultrasound as a non-invasive tool to monitor inflammatory bowel disease activity and guide clinical decision making
por: Dolinger, Michael T, et al.
Publicado: (2023)

Novel drug delivery systems for inflammatory bowel disease
por: Yasmin, Farah, et al.
Publicado: (2022)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?
por: Nishida, Atsushi, et al.
Publicado: (2021)

A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
por: Golovics, P, et al.
Publicado: (2022)

Management of inflammatory bowel disease with Clostridium difficile infection
por: D’Aoust, Julie, et al.
Publicado: (2017)

The Role of Vitamin D in Inflammatory Bowel Disease – Assessing Therapeutic and Preventive Potential of Supplementation and Food Fortification
por: Leskovar, Dunja, et al.
Publicado: (2018)

Inflammatory bowel disease and airway diseases
por: Vutcovici, Maria, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ddc4223gt6ft9flpk9711aq7qs